Asthma

Global Asthma and COPD Drug Market Research Report 2021-2025

Wed, 08 Sep 2021 15:45:00 +0000

Asthma and COPD are prevalent chronic inflammatory airway diseases that are responsible for a large global disease burden. In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Asthma and COPD Drug Report by Material, Application, and Geography – Global Forecast to 2025 is a professional and comprehensive research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China). In this report, the global Asthma and COPD Drug market is valued at USD XX million in 2021 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2021 to 2025. The report firstly introduced the Asthma and COPD Drug basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world’s main region market cond...

$3,200.00

Asthma Treatment Drugs Markets in China

Wed, 12 May 2021 15:00:05 +0000

China's demand for Asthma Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2010, 2015 and 2020) and long-term forecasts through 2025 and 2030 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interviews are ...

$4,000.00

Asthma Treatment Drugs Industry Forecasts - China Focus

Wed, 12 May 2021 15:00:05 +0000

This study focuses on China’s Asthma Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal inn...

$1,800.00

Asthma Treatment Drugs Companies in China

Wed, 12 May 2021 15:00:05 +0000

This study focuses on China’s Asthma Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suf...

$1,800.00

Asthma - Pipeline Review, H1 2020

Thu, 07 May 2020 13:13:49 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H1 2020, provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis b...

$2,500.00

Allergic Asthma Global Clinical Trials Review, H2, 2018

Fri, 07 Dec 2018 15:52:59 +0000

Summary

GlobalData's clinical trial report, “Allergic Asthma Global Clinical Trials Review, H2, 2018" provides an overview of Allergic Asthma clinical trials scenario. This report provides top line data relating to the clinical trials on Allergic Asthma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive...

$2,500.00

Acute Asthma Global Clinical Trials Review, H2, 2018

Fri, 07 Dec 2018 15:32:55 +0000

Summary

GlobalData's clinical trial report, “Acute Asthma Global Clinical Trials Review, H2, 2018" provides an overview of Acute Asthma clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Asthma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantag...

$2,500.00

Asthma - Pipeline Review, H2 2018

Thu, 29 Nov 2018 15:00:25 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H2 2018, provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis b...

$2,500.00

Digital Landscape: Asthma

Wed, 17 Oct 2018 16:06:20 +0000

Summary

The "Digital Landscape: Asthma", report analyzes digital activities undertaken by pharma in support of therapies for asthma.

Key Highlights

- US Patients: Strong feature-rich branded sites for both inhaled and injectable asthma therapies in the US. Most 2017 activity seen in the injectable therapy space, with the launch of branded and unbranded sites by AstraZeneca following approval of Fasenra, as well as activity from other companies with existing severe / allergic asthma therapies. Overall, the pharma-sponsored social media and mobile app landscapes for US patients are underdeveloped.
- US HCPs: Good brand support available for US HCPs in the asthma space from AstraZeneca, Teva and GSK. All new branded activity in 2017 was in the injectable space following approval of AstraZeneca’s Fasenra. Unbranded landscape is sparse with sites only detected for severe asthma from AstraZeneca and Sanofi / Regeneron. Social media activity is limited to corporate accounts and examples of good quality, pharma-sponsored mobile apps are lacking.<...

$6,000.00

Allergic Asthma Global Clinical Trials Review, H1, 2017

Fri, 12 May 2017 15:24:23 +0000

Summary

GlobalData's clinical trial report, “Allergic Asthma Global Clinical Trials Review, H1, 2017" provides an overview of Allergic Asthma clinical trials scenario. This report provides top line data relating to the clinical trials on Allergic Asthma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive...

$2,500.00

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Fri, 28 Apr 2017 10:35:57 +0000

Summary

Asthma is a chronic condition affecting the respiratory system, with disease occurrence linked to both genetic and environmental factors. It has significant global incidence and there is currently no cure. Pharmacotherapeutic intervention aims to provide patients with an increased level of disease control and reduce the severity of symptoms, and a number of inhalational therapeutic options are available. Current asthma treatment options are able to provide the majority of patients with a sufficient level of disease control. Additionally, scientific advancements through the development of combination and add-on therapeutics have provided patients with treatments that allow for a greater level of disease control. However, unmet need remains, in the form of patients that do not respond well to current therapeutics or therapeutic combinations. This group of patients accounts for the vast majority of global healthcare costs associated with asthma. Pipeline product development aims to improve upon current therapeutic options and provide options for satisfactory dis...

$6,995.00

Asthma - Market Insights, Epidemiology and Market Forecast-2023

Tue, 25 Apr 2017 20:08:12 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Asthma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Asthma forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Asthma till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Asthma market. • Identifying patient populations in the global “Asthmamarket to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Asthma therapeutics in each of the markets covered. • To understand the future market competition in the global Asthma...

$4,950.00

Epiomic Epidemiology Series: Asthma Forecast in 8 Major Markets 2016-2026

Thu, 06 Oct 2016 11:26:22 +0000

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Asthma in 8 Major Markets Asthma is a chronic disease involving airway inflammation, reversible airflow obstruction, and bronchial hyper-responsiveness. The condition is usually triggered by environmental factors of which the symptoms include: difficulty breathing, coughing, wheezing and in some cases a life-threatening asthma attack. Although the condition is not currently curable, the symptoms can be controlled to a more manageable state through stepping up and stepping down treatments according to disease progression. This report provides the current prevalent population for Asthma across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidi...

$6,400.00

Allergic Asthma - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Allergic Asthma - Pipeline Review, H2 2016’, provides an overview of the Allergic Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Asthma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor pre...

$2,000.00

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

Thu, 15 Sep 2016 20:01:35 +0000

Summary

The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in CF, where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The COPD and asthma treatment landscapes emplo...

$4,995.00

Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns

Wed, 01 Jun 2016 12:01:40 +0000

Summary

Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of aller...

$4,995.00

Asthma - Pipeline Review, H1 2016

Tue, 31 May 2016 09:45:03 +0000

Summary

Global Markets Direct’s, ‘Asthma - Pipeline Review, H1 2016’, provides an overview of the Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Asthma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releas...

$2,500.00

Allergic Asthma - Pipeline Review, H1 2016

Sat, 28 May 2016 19:12:44 +0000

Summary

Global Markets Direct’s, ‘Allergic Asthma - Pipeline Review, H1 2016’, provides an overview of the Allergic Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Asthma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor pre...

$2,000.00